Multivariate analysis--impact of SPM on progression-free survival
| Covariate . | N . | Hazard ratio . | 95% Hazard ratio confidence limits . | P-value . | |
|---|---|---|---|---|---|
| Time-dependent: SPM | |||||
| No | - | 1.00 | Reference | <.0001 | |
| Yes | - | 2.62 | 2.03 | 3.38 | <.0001 |
| Baseline covariates | |||||
| Gender | |||||
| Female | 1791 | 1.00 | Reference | .0742 | |
| Male | 2155 | 1.10 | 0.99 | 1.21 | .0742 |
| Karnofsky score | |||||
| ≥90 | 2076 | 1.00 | Reference | .1922 | |
| <90 | 1796 | 1.09 | 0.99 | 1.21 | .0939 |
| Missing | 74 | 1.20 | 0.81 | 1.77 | .3677 |
| ISS Stage at diagnosis | |||||
| Stage I | 1231 | 1.00 | Reference | <.0001 | |
| Stage II | 1104 | 1.27 | 1.11 | 1.46 | .0006 |
| Stage III | 712 | 1.68 | 1.45 | 1.95 | <.0001 |
| Missing | 899 | 1.28 | 1.11 | 1.48 | .0007 |
| Cytogenetics | |||||
| Standard/Normal Risk | 2496 | 1.00 | Reference | <.0001 | |
| High risk | 1114 | 1.52 | 1.35 | 1.69 | <.0001 |
| Missing | 336 | 1.34 | 1.12 | 1.61 | .0017 |
| Lines of chemotherapy | |||||
| 1 | 2856 | 1.00 | Reference | <.0001 | |
| 2+ | 929 | 1.28 | 1.14 | 1.45 | <.0001 |
| Missing | 161 | 0.74 | 0.54 | 1.01 | .0574 |
| Disease status before transplant | |||||
| sCR/CR | 611 | 1.00 | Reference | <.0001 | |
| VGPR | 1538 | 1.22 | 1.03 | 1.44 | .0206 |
| PR | 1520 | 1.53 | 1.30 | 1.81 | <.0001 |
| SD/PD/Relapse | 255 | 1.82 | 1.45 | 2.27 | <.0001 |
| Missing | 22 | 0.95 | 0.39 | 2.32 | .9151 |
| Time from diagnosis to HCT | |||||
| 0-6 mo | 1367 | 1.00 | Reference | <.0001 | |
| 6-12 mo | 1861 | 0.93 | 0.83 | 1.04 | .2134 |
| 12-24 mo | 445 | 1.07 | 0.90 | 1.27 | .4431 |
| 24+ mo | 273 | 1.52 | 1.25 | 1.85 | <.0001 |
| Covariate . | N . | Hazard ratio . | 95% Hazard ratio confidence limits . | P-value . | |
|---|---|---|---|---|---|
| Time-dependent: SPM | |||||
| No | - | 1.00 | Reference | <.0001 | |
| Yes | - | 2.62 | 2.03 | 3.38 | <.0001 |
| Baseline covariates | |||||
| Gender | |||||
| Female | 1791 | 1.00 | Reference | .0742 | |
| Male | 2155 | 1.10 | 0.99 | 1.21 | .0742 |
| Karnofsky score | |||||
| ≥90 | 2076 | 1.00 | Reference | .1922 | |
| <90 | 1796 | 1.09 | 0.99 | 1.21 | .0939 |
| Missing | 74 | 1.20 | 0.81 | 1.77 | .3677 |
| ISS Stage at diagnosis | |||||
| Stage I | 1231 | 1.00 | Reference | <.0001 | |
| Stage II | 1104 | 1.27 | 1.11 | 1.46 | .0006 |
| Stage III | 712 | 1.68 | 1.45 | 1.95 | <.0001 |
| Missing | 899 | 1.28 | 1.11 | 1.48 | .0007 |
| Cytogenetics | |||||
| Standard/Normal Risk | 2496 | 1.00 | Reference | <.0001 | |
| High risk | 1114 | 1.52 | 1.35 | 1.69 | <.0001 |
| Missing | 336 | 1.34 | 1.12 | 1.61 | .0017 |
| Lines of chemotherapy | |||||
| 1 | 2856 | 1.00 | Reference | <.0001 | |
| 2+ | 929 | 1.28 | 1.14 | 1.45 | <.0001 |
| Missing | 161 | 0.74 | 0.54 | 1.01 | .0574 |
| Disease status before transplant | |||||
| sCR/CR | 611 | 1.00 | Reference | <.0001 | |
| VGPR | 1538 | 1.22 | 1.03 | 1.44 | .0206 |
| PR | 1520 | 1.53 | 1.30 | 1.81 | <.0001 |
| SD/PD/Relapse | 255 | 1.82 | 1.45 | 2.27 | <.0001 |
| Missing | 22 | 0.95 | 0.39 | 2.32 | .9151 |
| Time from diagnosis to HCT | |||||
| 0-6 mo | 1367 | 1.00 | Reference | <.0001 | |
| 6-12 mo | 1861 | 0.93 | 0.83 | 1.04 | .2134 |
| 12-24 mo | 445 | 1.07 | 0.90 | 1.27 | .4431 |
| 24+ mo | 273 | 1.52 | 1.25 | 1.85 | <.0001 |